Impact of Antithrombotic Therapy on Survival Outcomes in Advanced Melanoma Patients Receiving Targeted Therapy: Insights from the Prospective Multicenter ADOReg Registry

Le résumé fourni par la source

Background: The standard therapy for advanced cutaneous melanoma involves immune checkpoint inhibition (ICI). Despite its efficacy, therapy response can be slow, leading to potential worsening of disease before stabilization occurs. For BRAF mutated melanoma, targeted therapy (TT, BRAF+MEK inhibitors) offers an alternative with rapid therapy response, especially in patients with extensive tumor burden. However, not all patients benefit equally. Our recently published data suggests improved progression-free survival (PFS) and overall survival (OS) of advanced melanoma patients undergoing ICI alongside anticoagulation (AC).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.